CSP #2008 - Pentoxifylline in Diabetic Kidney Disease
Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys from damage due to diabetes and other diseases. Pentoxifylline in Diabetic Kidney Disease is a study to bee conducted in 40 VA hospitals across the nation to determine definitively whether or not PTX can prevent worsening of kidney disease and delay death in patients with diabetic kidney disease.
• Type-2 diabetes.
• Meet one of the following categories at a time that is greater than 90 days prior to randomization:
‣ Group I: eGFR 15 to less than 30 mL/min/1.73 m2 regardless of the degree of albuminuria/proteinuria, or
⁃ Group II: eGFR 30 to less than 45 mL/min/1.73 m2 with UACR greater than or equal to (\>) 30 mg/g or UPCR greater than or equal to (\>) 150 mg/g, or
⁃ Group III: eGFR 45 to less than 60 mL/min/1.73 m2 with UACR greater than or equal to (\>) 300 mg/g or UPCR greater than or equal to (\>)500 mg/g
• Participants need to be in one of the following categories at the time of randomization:
‣ Group I: eGFR 15 to less than 30 mL/min/1.73 m2, or
⁃ Group II: eGFR 30 to less than 45 mL/min/1.73 m2 with UACR greater than or equal to (\>) 30 mg/g, or
⁃ Group III: eGFR 45 to less than 60 mL/min/1.73 m2 with UACR greater than or equal to (\>) 300 mg/g
∙ Participants must be a United States Veteran, currently receiving care at a VA hospital with a local study team.